查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1634626

潜伏性结核病检测市场：现况分析及未来预测（2024-2032）

Latent TB Testing Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计预测期内（2024-2032 年），潜伏性结核病检测市场将以 7.8% 的复合年增长率大幅成长。这主要是因为全球结核病发生率不断上升，检测潜伏性结核病以预防活动性结核病的需求日益增加。此外，IGRA等诊断工具的改进提高了其在高风险群体中的有效性和利用率。此外，政府发起的结核病控制运动和强制性筛检也促进了市场的成长。

根据测试类型，市场分为结核菌素皮肤试验 (TST) 和干扰素-γ释放试验 (IGRA)。干扰素-γ释放试验（IGRA）将在2023年占据市场的大部分占有率。干扰素-γ释放试验（IGRA）几乎只在高收入国家和需要保护的人口中进行。除此之外，各公司也使用 IGRA 提供新的、更精确的测试，例如 QuantiFERON-TB 和 T-SPOT.TB，并提高自动化诊断过程的效率。我们的目标是与医疗机构合作，将 IGRA 纳入常规筛检，并提高 PoA 中 IGRA 的可用性。人们对精确​​的诊断设备的需求很高，而且这项技术与当前和未来的医疗保健系统高度相关。

2024 年 3 月 18 日，QIAGEN (NYSE: QGEN; 法兰克福证券交易所代码：QIA) 宣布与国际小组医生协会 (IPPA) 建立合作伙伴关係，以支持和教育世界各地的小组医生瞭解最新的结核病筛检要求。特别是，我们将重点关注新的干扰素-γ释放试验（IGRA）的要求以及对患者和医疗保健提供者的相关益处。

根据应用，市场分为结核病患者家庭接触者 (HHC)、爱滋病毒感染者 (PLHIV) 和其他。预测期内（2024-2032 年），爱滋病毒感染率预计将以显着的复合年增长率成长。爱滋病毒感染者罹患活动性结核病的风险很高，因此需要定期进行准确的检测，因而是潜伏性结核病检测的最大消费者。近期，爱滋病护理计画中结核病诊断的全球扩展增加了对诸如 IGRA 之类的性别特定且高度准确的测试的需求。公司正在与爱滋病诊所和非政府组织建立合作伙伴关係，提供特定的检测解决方案，并透过向这一高风险群体提供价格合理、方便可扩展的检测解决方案来招募患者。

根据最终用户，市场分为诊断实验室、医院/诊所以及学术和研究机构。 2023 年，诊断实验室将占据市场的大部分占有率。诊断实验室是潜伏性结核病检测中心的主要作用，尤其是在城市和半城市地区。扩大先进诊断设备的使用范围并确保结果的准确性推动了成长。为了支援这一领域，公司提供和安装 IGRA 自动化系统，实施高效实验室营运解决方案，并提供将结果轻鬆整合到临床环境中的技术。

为了更瞭解潜伏性结核病检测的市场采用情况，根据北美（美国、加拿大和北美其他地区）、欧洲（德国、法国、英国、西班牙、义大利和欧洲其他地区）、亚太地区（中国、日本、印度和亚太地区其他地区）和世界其他地区的全球存在情况对市场进行了分析。预计预测期内（2024-2032 年）亚太地区将以显着的复合年增长率成长。这是由于结核病发病率高、人们对结核病认识的提高以及全国为消灭结核病所做的努力。根据世界卫生组织 (WHO) 的数据，2022 年八个国家的结核病病例占世界结核病病例的三分之二以上：印度（27%）、印尼（10%）、中国（7.1%）、菲律宾（7.0%）、巴基斯坦（5.7%）、奈及利亚（4.5%）、孟加拉（3.6%）和刚果民主共和国（3.0%）。此外，印度、中国等国家也在国际组织合作下进行大规模筛检。例如，这可能包括提供低成本的诊断解决方案、与政府机构合作以及增加产品有限地区的市场覆盖率。在城市地区，从传统 TST 向先进的 IGRA 的转变也支持了市场成长。

在市场上营运的主要公司包括 QIAGEN、Revvity、Abbott、BIOMERIEUX、Serum Institute of India Pvt.Ltd.、Lionex GmbH、SD Biosensor, INC.、Cepheid、Wantai BioPharm 和 AdvaCare Pharma。

目录

第一章 市场概览

  • 市场定义
  • 主要目的
  • 利害关係人
  • 限制

第 2 章 分析方法或假设

  • 分析过程
  • 分析法
  • 受访者资料

第 3 章执行摘要

  • 产业摘要
  • 各细分市场的展望
    • 市场成长强劲
  • 区域展望

第 4 章 市场动态

  • 驱动程式
  • 机会
  • 阻碍因素
  • 趋势
  • PESTEL 分析
  • 需求方分析
  • 供给面分析
    • 併购 (M&A)
    • 投资场景
    • 产业洞察：领先的新创公司及其独特策略

第 5 章 定价分析

  • 价格分析：依地区
  • 影响价格的因素

第六章 全球潜伏性结核病检测市场收入（2022-2032）

第 7 章。
  • 结核菌素皮肤试验 (TST)
  • 干扰素-γ释放试验（IGRA）

第 8 章 依应用划分的市场分析

  • 结核病患者的家庭接触者 (HHC)
  • 爱滋病毒感染者 (PLHIV)
  • 其他

第 9 章 最终使用者的市场分析

  • 诊断实验室
  • 医院/诊所
  • 学术和研究机构

第 10 章 各区域市场分析

  • 北美洲
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
    亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第 11 章 价值链分析

  • 边际分析
  • 市场参与者名单

第 12 章 竞争格局

  • 竞争资讯中心
  • 公司市场定位分析
  • 波特五力分析

第 13 章 公司简介

    凯杰公司
    • 公司概况
    • 主要财务指标
    • SWOT 分析
    • 产品组合
    • 近期趋势
  • Revvity
  • Abbott
  • BIOMERIEUX
  • Serum Institute of India Pvt. Ltd.
  • Lionex GmbH
  • SD Biosensor, INC.
  • Cepheid
  • Wantai BioPharm
  • AdvaCare Pharma

第 14 章 缩写与先决条件

第 15 章附录

简介目录
Product Code: UMHE213123

Latent TB Testing determines individuals with asymptomatic Mycobacterium tuberculosis infection who are likely to develop overt TB. Screening tests include the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs), which identify a body's reaction to the bacteria. These tests are important in the prevention of TB epidemics among multiple risk groups such as the immunocompromised as well as the healthcare givers.

The Latent TB Testing Market is expected to grow with a significant CAGR of 7.8% during the forecast period (2024-2032). This is mainly due to the increasing rates of tuberculosis across the world increasing the need to detect latent TB to prevent active TB. Also, improvements in diagnostic tools like IGRAs increase the effectiveness and utilization in high-risk groups. In addition, TB control campaigns supported by the government and compulsory screening norms also contribute to the growth of the market.

Based on the test type, the market is segmented into Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA). The Interferon Gamma Released Assay (IGRA) held a significant share of the market in 2023. The Interferon Gamma Released Assay (IGRA). It is implemented almost exclusively in high-income countries and among the populations in need of protection. Adding to this, IGRA is used by companies to provide new, more precise tests, such as QuantiFERON-TB and T-SPOT.TB, and to increase the efficiency of diagnostic process automation. They aim to cooperate with healthcare organizations to include IGRAs in regular check-ups and increase the availability of IGRAs via point of care. This technology has high relevance in the current and future healthcare systems since there is a great need for accurate diagnostic equipment.

On March 18, 2024, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.

Based on application, the market is segmented into household contacts (HHC) of tuberculosis (TB) patients, people living with HIV (PLHIV), and others. People living with HIV are expected to grow with a significant CAGR during the forecast period (2024-2032). The PLHIV segment is one of the primary consumers in the latent TB testing market because such patients have a higher risk of developing active TB and, therefore, require regular and accurate tests. The recent expansion of tuberculosis diagnostics in HIV care programs worldwide has boosted the need for gender-precise and accurate tests such as IGRAs. Companies adopt by developing partnerships with HIV clinics and NGOs to deliver specific test solutions and by providing affordable easy-to-scale testing solutions to this risky group.

Based on the end user, the market is segmented into diagnostic laboratories, hospitals/clinics, and academic & research institutions. Diagnostic Laboratories held a significant share of the market in 2023. Diagnostic laboratories are major players as the testing centers for latent TB, especially in urban and semi-urban settings. They enhance growth by expanding access to high-level diagnostic equipment and guaranteeing the accuracy of results. To support this segment, companies supply and install IGRA automation systems, implement solutions for efficient lab operations, and provide technology for easy integration of the results into the clinical environment.

For a better understanding of the market adoption of Latent TB Testing, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is due to a high tuberculosis incidence rate, improved understanding of the disease, and national efforts to eliminate the disease. As per the World Health Organization, In 2022, eight countries accounted for more than two-thirds of global TB cases: India (27%), Indonesia (10%), China (7.1%), the Philippines (7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of the Congo (3.0%). Adding to this, large-scale screening is being carried out in countries such as India and China with the help of international organizations. Examples include offering low-cost diagnostic solutions, forming alliances with government organizations, and increasing market coverage to areas that have limited access to the products. A shift from conventional TSTs to advanced IGRAs within the urban regions also supports the growth of the market.

Some of the major players operating in the market include QIAGEN, Revvity, Abbott, BIOMERIEUX, Serum Institute of India Pvt. Ltd., Lionex GmbH, SD Biosensor, INC., Cepheid, Wantai BioPharm, AdvaCare Pharma.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Latent TB Testing Market
  • 2.2. Research Methodology of the Latent TB Testing Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL LATENT TB TESTING MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY TEST TYPE

  • 7.1. Tuberculin Skin Test (TST)
  • 7.2. Interferon Gamma Released Assay (IGRA)

8.MARKET INSIGHTS BY APPLICATION

  • 8.1. Household Contacts (HHC) of Tuberculosis (TB) Patients
  • 8.2. People Living with HIV (PLHIV)
  • 8.3. Others

9.MARKET INSIGHTS BY END USER

  • 9.1. Diagnostic Laboratories
  • 9.2. Hospitals/clinics
  • 9.3. Academic & Research Institutions

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. France
    • 10.2.3. UK
    • 10.2.4. Spain
    • 10.2.5. Italy
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of APAC
  • 10.4. Rest of the World

11.VALUE CHAIN ANALYSIS

  • 11.1. Marginal Analysis
  • 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

  • 13.1. QIAGEN
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Revvity
  • 13.3. Abbott
  • 13.4. BIOMERIEUX
  • 13.5. Serum Institute of India Pvt. Ltd.
  • 13.6. Lionex GmbH
  • 13.7. SD Biosensor, INC.
  • 13.8. Cepheid
  • 13.9. Wantai BioPharm
  • 13.10. AdvaCare Pharma

14.ACRONYMS & ASSUMPTION

15.ANNEXURE